These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35585949)

  • 21. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
    Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
    J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.
    Momoi M; Hiraide T; Shinya Y; Momota H; Fukui S; Kawakami M; Itabashi Y; Fukuda K; Kataoka M
    Ther Adv Respir Dis; 2021; 15():1753466621995048. PubMed ID: 33627044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension.
    Furukawa A; Tamura Y; Iwahori H; Goto M; Ohashi N; Okabe T; Kawamura A
    BMC Pulm Med; 2017 Oct; 17(1):135. PubMed ID: 29073911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different efficacy of inhaled and oral medications in pulmonary hypertension.
    AbuHalimeh BJ; Parambil JG; Tonelli AR
    Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transition from IV epoprostenol to oral treprostinil in a patient with group 1 pulmonary arterial hypertension.
    Sarangarm P; Elwood K
    Am J Health Syst Pharm; 2021 Nov; 78(23):2110-2115. PubMed ID: 34100906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway.
    Menon AA; Sahay S; Braverman LE; Farber HW
    Lung; 2019 Dec; 197(6):761-768. PubMed ID: 31696306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
    Denton CP; Hachulla É; Riemekasten G; Schwarting A; Frenoux JM; Frey A; Le Brun FO; Herrick AL;
    Arthritis Rheumatol; 2017 Dec; 69(12):2370-2379. PubMed ID: 29193819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension.
    Colglazier E; Stevens L; Parker C; Nawaytou HM; Amin EK; Becerra J; Steurer M; Fineman JR
    Pulm Circ; 2022 Oct; 12(4):e12159. PubMed ID: 36514390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
    Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
    Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.
    Koo R; Lo J; Bock MJ
    Cardiol Young; 2019 Jun; 29(6):849-851. PubMed ID: 31379316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?
    El Yafawi R; Wirth JA
    Curr Hypertens Rep; 2017 Oct; 19(12):97. PubMed ID: 29071454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
    Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upfront triple oral combination therapy including selexipag in a high-risk patient with idiopathic pulmonary arterial hypertension: a case report.
    Rossi S; Pietrangelo C; Pierdomenico SD; Giuliani L
    Eur Heart J Case Rep; 2020 Oct; 4(5):1-5. PubMed ID: 33204960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
    Hardin EA; Chin KM
    Drug Des Devel Ther; 2016; 10():3747-3754. PubMed ID: 27895464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
    Honorato Pérez J
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.
    Coghlan JG; Channick R; Chin K; Di Scala L; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin V; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Gaine S
    Am J Cardiovasc Drugs; 2018 Feb; 18(1):37-47. PubMed ID: 29307087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of sigmoidectomy for sigmoid colon cancer with severe pulmonary arterial hypertension associated with mixed tissue connected disease: A case report.
    Takagi Y; Koyama M; Miyagawa Y; Kitazawa M; Kimura K; Soejima Y
    Int J Surg Case Rep; 2021 Jun; 83():105906. PubMed ID: 34023548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series.
    Blissett S; Blusztein D; Mahadevan VS
    Eur Heart J Case Rep; 2020 Dec; 4(6):1-7. PubMed ID: 33442633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients.
    Cui X; Lu W; Zhang D; Qie L; Li H; Li X; Liu H; Ji Q
    Front Cardiovasc Med; 2022; 9():991586. PubMed ID: 36204579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.